cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.22815068.v1
title: Additional file 1 of Genetic basis of geographical differentiation and breeding selection for wheat plant architecture traits

description: Additional file 1: Figure S1. Phylogenetic relationships and population structures. Figure S2. Geographical distribution and breeding selection of the haplotype blocks associated with the length of the second internode on chromosome 1A. Figure S3. Geographical distribution and breeding selection of the haplotype blocks associated with the length of the third internode on chromosome 3D. Figure S4. Geographical distribution and breeding selection of the haplotype blocks associated with the length of the fourth internode on chromosome 2A. Figure S5. The evolutionary relationship of the haplotypes for the loci for the length of second internode, third internode, four internode.
DOI: 10.6084/m9.figshare.11805072
title: Additional file 3 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 3: Differentially expressed miRNAs in mock-infected and DHAV-3-infected duckling liver.
DOI: 10.6084/m9.figshare.11805072.v1
title: Additional file 3 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 3: Differentially expressed miRNAs in mock-infected and DHAV-3-infected duckling liver.
DOI: 10.6084/m9.figshare.11805075
title: Additional file 4 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 4: GO annotation of the predicted target genes of all miRNAs in this study.
DOI: 10.6084/m9.figshare.11805075.v1
title: Additional file 4 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 4: GO annotation of the predicted target genes of all miRNAs in this study.
DOI: 10.6084/m9.figshare.11805078
title: Additional file 5 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 5: KEGG enrichment analysis of target genes annotated for miRNAs differentially expressed in mock- and DHAV-3-infected duckling liver.
DOI: 10.6084/m9.figshare.11805078.v1
title: Additional file 5 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 5: KEGG enrichment analysis of target genes annotated for miRNAs differentially expressed in mock- and DHAV-3-infected duckling liver.
DOI: 10.6084/m9.figshare.11805081
title: Additional file 6 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 6: Differentially expressed miRNAs predicted to target the DHAV-3 genome.
DOI: 10.6084/m9.figshare.11805081.v1
title: Additional file 6 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 6: Differentially expressed miRNAs predicted to target the DHAV-3 genome.
DOI: 10.6084/m9.figshare.11805084
title: Additional file 7 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 7: Overview of mRNA-Seq in the mock-infected and DHAV-3-infected libraries.
DOI: 10.6084/m9.figshare.11805084.v1
title: Additional file 7 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 7: Overview of mRNA-Seq in the mock-infected and DHAV-3-infected libraries.
DOI: 10.6084/m9.figshare.12853661
title: SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

description: The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19.
DOI: 10.6084/m9.figshare.12853661.v1
title: SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

description: The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19.
DOI: 10.6084/m9.figshare.12853661.v2
title: SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

description: The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19.
DOI: 10.6084/m9.figshare.12853661.v4
title: SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

description: The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19.
DOI: 10.6084/m9.figshare.12853661.v3
title: SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

description: The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19.
DOI: 10.6084/m9.figshare.11805093
title: Additional file 8 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 8: Differentially expressed genes in mock-infected and DHAV-3-infected duckling liver.
DOI: 10.6084/m9.figshare.11805093.v1
title: Additional file 8 of Immune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings

description: Additional file 8: Differentially expressed genes in mock-infected and DHAV-3-infected duckling liver.
DOI: 10.6084/m9.figshare.12853673
title: Development of an automatic integrated gene detection system for novel severe acute respiratory syndrome-related coronavirus (SARS-CoV2)

description: In December 2019, Wuhan, China suffered a serious outbreak of a novel coronavirus infectious disease (COVID) caused by novel severe acute respiratory syndrome-related coronavirus (SARS-CoV 2). To quickly identify the pathogen, we designed and screened primer sets, and established a sensitive and specific qRT-PCR assay for SARS-CoV 2; the lower limit of detection (LOD) was 15 (95% CI: 9.8–21) copies per reaction. We combined this qRT-PCR assay with an automatic integration system for nucleic acid extraction and amplification, thereby establishing an automatic integrated gene detection system (AIGS) for SARS-CoV 2. Cross reactive analysis performed in 20 other respiratory viruses and 37 nasopharyngeal swabs confirmed a 100% specificity of the assay. Using two fold diluted SARS-CoV 2 culture, the LOD of AIGS was confirmed to be 365 copies/ml (95% CI: 350–375), which was Comparable to that of conventional qRT-PCR (740 copies/ml, 95% CI: 690–750). Clinical performances of AIGS assay were assessed in 266 suspected COVID-19 clinical respiratory tract samples tested in parallel with a commercial kit. The clinical sensitivity of the AIGS test was 97.62% (95% CI: 0.9320–0.9951) based on the commercial kit test result, and concordance analysis showed a high agreement in SARS-CoV-2 detection between the two assays, Pearson R was 0.9623 (95% CI: 0.9523–0.9703). The results indicated that this AIGS could be used for rapid detection of SARS-CoV 2. With the advantage of simple operation and less time consuming, AIGS could be suitable for SARS-CoV2 detection in primary medical institutions, thus would do a great help to improve detection efficiency and control the spread of COVID-19.
DOI: 10.6084/m9.figshare.12853673.v2
title: Development of an automatic integrated gene detection system for novel severe acute respiratory syndrome-related coronavirus (SARS-CoV2)

description: In December 2019, Wuhan, China suffered a serious outbreak of a novel coronavirus infectious disease (COVID) caused by novel severe acute respiratory syndrome-related coronavirus (SARS-CoV 2). To quickly identify the pathogen, we designed and screened primer sets, and established a sensitive and specific qRT-PCR assay for SARS-CoV 2; the lower limit of detection (LOD) was 15 (95% CI: 9.8–21) copies per reaction. We combined this qRT-PCR assay with an automatic integration system for nucleic acid extraction and amplification, thereby establishing an automatic integrated gene detection system (AIGS) for SARS-CoV 2. Cross reactive analysis performed in 20 other respiratory viruses and 37 nasopharyngeal swabs confirmed a 100% specificity of the assay. Using two fold diluted SARS-CoV 2 culture, the LOD of AIGS was confirmed to be 365 copies/ml (95% CI: 350–375), which was Comparable to that of conventional qRT-PCR (740 copies/ml, 95% CI: 690–750). Clinical performances of AIGS assay were assessed in 266 suspected COVID-19 clinical respiratory tract samples tested in parallel with a commercial kit. The clinical sensitivity of the AIGS test was 97.62% (95% CI: 0.9320–0.9951) based on the commercial kit test result, and concordance analysis showed a high agreement in SARS-CoV-2 detection between the two assays, Pearson R was 0.9623 (95% CI: 0.9523–0.9703). The results indicated that this AIGS could be used for rapid detection of SARS-CoV 2. With the advantage of simple operation and less time consuming, AIGS could be suitable for SARS-CoV2 detection in primary medical institutions, thus would do a great help to improve detection efficiency and control the spread of COVID-19.
DOI: 10.6084/m9.figshare.12853673.v1
title: Development of an automatic integrated gene detection system for novel severe acute respiratory syndrome-related coronavirus (SARS-CoV2)

description: In December 2019, Wuhan, China suffered a serious outbreak of a novel coronavirus infectious disease (COVID) caused by novel severe acute respiratory syndrome-related coronavirus (SARS-CoV 2). To quickly identify the pathogen, we designed and screened primer sets, and established a sensitive and specific qRT-PCR assay for SARS-CoV 2; the lower limit of detection (LOD) was 14.8 (95% CI: 9.8–21) copies per reaction. We combined this qRT-PCR assay with an automatic integration system for nucleic acid extraction and amplification, thereby establishing an automatic integrated gene detection system (AIGS) for SARS-CoV 2. Cross reactive analysis performed in 20 other respiratory viruses and 37 nasopharyngeal swabs confirmed a 100% specificity of the assay. Using two fold diluted SARS-CoV 2 culture, the LOD of AIGS was confirmed to be 365 copies/ml (95% CI: 351–375), which was Comparable to that of conventional q RT–PCR (740 copies/ml, 95% CI: 689–750). Clinical performances of AIGS assay were assessed in 266 suspected COVID-19 clinical respiratory tract samples tested in parallel with a commercial kit. The clinical sensitivity of the AIGS test was 97.62% (95% CI: 0.9320–0.9951) based on the commercial kit test result, and concordance analysis showed a high agreement in SARS-CoV-2 detection between the two assays, Pearson R was 0.9623 (95% CI: 0.9523–0.9703). The results indicated that this AIGS could be used for rapid detection of SARS-CoV 2. With the advantage of simple operation and less time consuming, AIGS could be suitable for SARS-CoV2 detection in primary medical institutions, thus would do a great help to improve detection efficiency and control the spread of COVID-19.
DOI: 10.6084/m9.figshare.22815144
title: Additional file 2 of Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

description: Additional file 2: Table S1. Description of Landmark and Surveillance strategy of each included study. NA: Not applicable. *: The preferred time point as Landmark.
DOI: 10.6084/m9.figshare.22815144.v1
title: Additional file 2 of Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

description: Additional file 2: Table S1. Description of Landmark and Surveillance strategy of each included study. NA: Not applicable. *: The preferred time point as Landmark.
DOI: 10.6084/m9.figshare.22815153.v1
title: Additional file 5 of Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

description: Additional file 5: Table S2. Information of each included study for meta-analysis between landmark and surveillance strategy. Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative. *: After excluding patients with small-cell lung cancer, the data for Chaudhuri AA 2017 changed to: landmark: TP = 17, TN = 0, FN = 1, TN = 16; surveillance: TP = 8, TN = 0, FN = 0, TN = 8. ψ: Patients who have been reported in Chaudhuri AA 2017 were excluded. ξ: After using 2 h after surgery as preferred landmark in Peng M 's study, the landmark results changed to: TP = 13, FP = 5, FN = 15, TN = 36.
DOI: 10.6084/m9.figshare.22815156
title: Additional file 6 of Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

description: Additional file 6: Table S3. Baseline characteristics of patients in included studies.
DOI: 10.6084/m9.figshare.22815156.v1
title: Additional file 6 of Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

description: Additional file 6: Table S3. Baseline characteristics of patients in included studies.
DOI: 10.6084/m9.figshare.22815153
title: Additional file 5 of Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

description: Additional file 5: Table S2. Information of each included study for meta-analysis between landmark and surveillance strategy. Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative. *: After excluding patients with small-cell lung cancer, the data for Chaudhuri AA 2017 changed to: landmark: TP = 17, TN = 0, FN = 1, TN = 16; surveillance: TP = 8, TN = 0, FN = 0, TN = 8. ψ: Patients who have been reported in Chaudhuri AA 2017 were excluded. ξ: After using 2 h after surgery as preferred landmark in Peng M 's study, the landmark results changed to: TP = 13, FP = 5, FN = 15, TN = 36.
DOI: 10.13145/bacdive123906.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123906.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123907.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123907.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123908.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123908.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123909.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123909.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123910.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123910.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123911.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123911.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123912.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123912.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123913.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123913.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123914.20220920.7
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive123914.20221219.7.1
title: Streptomyces sp.

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.